On the afternoon of April 16, Guangdong Cephalos Pharmaceutical Co Ltd, which is a wholly-owned subsidiary ofGuangdong Jincheng Jinsu Pharmaceutical Co Ltd, held a signing ceremony withNational Health Technology Park (NHTP) for the class I drug "Litazolidone (LT-01)" to settle in Zhongshan's Torch Development Zone.

"Litazolidone (LT-01)" is mainly used for the treatment of hospital- or community-acquired pneumonia caused by the Staphylococcus bacteria. It is a new compound-structured antibiotic, which is not been released to domestic or foreign markets. It is currently under preparations for the phase I clinical study. The project was developed by the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences.

Guangdong Jincheng Jinsu Pharmaceutical Co Ltd, a subsidiary of the listed company Jincheng Pharmaceutical Group Co Ltd, is an innovative enterprise in the field of cephalosporin preparations in China. The company signed a project with NHTP at the 2020 Zhongshan Trade and Investment Fair on March 28. This project, with a total investment of 800 million yuan, details plans to build the headquarters of Jincheng Jinsu Pharmaceutical Co Ltd in Zhongshan, the output value of which is expected to exceed 3 billion yuan within 5 years.

The health industry is one of the three strategic development pillars of Torch Development Zone. Due to the epidemic, NHTP only resumed production in March and realized a monthly output value of 1.062 billion yuan, achieving an unexpected growth of 14% from a year earlier.